Healthcare Equipment and Supplies
Company Overview of IDEV Technologies, Inc.
IDEV Technologies, Inc. engages in the development and commercialization of minimally invasive medical devices for interventional radiology, vascular surgery, and cardiology. It offers SUPERA Transhepatic Biliary System, a stent for palliative treatment of biliary strictures produced by malignant neoplasms. The company also provides GliderfleX OTW PTA, a balloon catheter to support angioplasty needs. IDEV Technologies, Inc. was founded in 2006 and is based in Webster, Texas. The company has an additional office in Beuningen, the Netherlands. As of August 21, 2013, IDEV Technologies, Inc. operates as a subsidiary of Abbott Laboratories.
253 Medical Center Boulevard
Webster, TX 77598
Founded in 2006
Key Executives for IDEV Technologies, Inc.
Chief Financial Officer and Executive Vice President
Senior Vice President of Operations
Vice President of Finance and Administration
Compensation as of Fiscal Year 2013.
IDEV Technologies, Inc. Key Developments
IDEV Technologies, Inc. Announces Results from Revascularization
Jan 31 13
IDEV Technologies, Inc. announced results from a new study by physicians from Tucson, Arizona, which were reported at last week's LINC meeting in Leipzig, Germany. The data matched previously reported results with the Supera Stent in other studies, but in a group of patients with more advanced peripheral disease. One hundred forty-seven patients from Tucson were included in the analysis. Long lesions were studied, with the mean lesion length of their superficial femoral artery (SFA) and popliteal artery disease of 18.4 cm, which was treated by an average stent length of 19.7 cm. The study included patients with TASC II C & D disease (28 and 33% respectively). In addition, 35% of the patients had tissue loss and were accounted for via Rutherford Becker 5 & 6 classification, and 53% of all patients had chronic total occlusions (CTO). The overall primary patency rate, measured by duplex ultrasound, at one year follow-up was 88%. Zero fractures were found within a subgroup analysis of 47 patients which received follow-up x-ray evaluation.
IDEV Technologies, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 09:30 AM
Nov 24 12
IDEV Technologies, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 09:30 AM. Venue: The New York Palace, 455 Madison Avenue, New York, NY 10022, United States.
IDEV Technologies, Inc. Announces Positive Two-Year Clinical Outcomes from Long Term Registry of the SUPERA(R) Stent in Femoropopliteal Artery Disease
Oct 11 12
IDEV Technologies, Inc. announced positive two-year clinical outcomes of the SUPERA(R) Peripheral Stent System from SUPERA 500, a long-term registry which was presented at the 10(th) VIVA Conference held in Las Vegas, Nevada by principal investigator, Dierk Scheinert, M.D., Chairman for the Center of Vascular Medicine at Park Hospital and Heart Center in Leipzig, Germany. A total of 495 patients with 528 lesions were enrolled in the registry which included a very challenging patient population. 51% of patients included had diabetes; 53% of patients had occlusive femoropopliteal disease; Mean stented segment length was 12.6 cm with approximately 69% being Rutherford Becker Class 3 or higher; 13% of the patients had experienced tissue loss; 53% of the treated lesions were classified as TASC D. The SFA and popliteal arteries are exposed to significant mechanical stress with bending and rotation of the knee, and represent a harsh environment for any endovascular device. An ideal stent for use in these areas should offer a great range of motion without interrupting the anatomical function of the arteries. The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).
Similar Private Companies By Industry
Recent Private Companies Transactions
July 15, 2013